Main results
- Internal R&D expenditure increased by 14.4% in 2024, reaching 3,144 million euros.
- The full-time equivalent personnel dedicated to internal R&D activities in Biotechnology was 39,780.6. 59.7% were women.
Expenditure in internal R&D activities related to Biotechnology reached 3,144 million euros in 2024, an increase of 14.4% as compared with the previous year. This expenditure represented 13.1% of the total spending on internal R&D activities.
By execution sector, expenditure in the Public Administration sector increased by 23.1%, while expenditure in the Business sector increased by 14.0%.
Regarding the total expenditure on internal R&D activities in Biotechnology, the Business sector showed the highest percentage (46.5% of the total). Behind them were Public Administration (30.9%), Higher Education (22.2%) and Private Non-Profit Institutions (IPSFL), with 0.4%.
Year 2024. Thousands of euros
Internal R&D activities related to Biotechnology were financed in 2024, mainly by the Business (45.4% of the total) and the Public Administration sectors (38.6%).
Year 2024. Thousands of euros
In 2024, the full-time equivalent (FTE) personnel dedicated to internal R&D activities in Biotechnology was 39,780.6. 59.7% of the personnel were women.
The research staff consisted of 25,414.2 individuals as FTE personnel. 56.9% were women.
Year 2024. Full-time Equivalence
Among the final application areas of products obtained from the use of different types of biotechnologies, Human Health and Food stood out, accounting for 52.1% and 30.2% of the total units, respectively.
Year 2024. Percentage
The Autonomous Communities with the highest expenditure on internal R&D activities in Biotechnology in 2024 were Cataluña (33.8% of the total), Comunidad de Madrid (24.4%) and Andalucía (9.2%).
Year 2024. Thousands of euros
(*) Rest of sectors: Public Administration, NPPI and Higher Education.
(.) Numeric data equal to zero not resulting from rounding.
(..) Data not available due to statistical confidentiality.
The data published today are final. All results are available on INEBase.
In accordance with the Commission's Delegated Regulation (EU) 2023/137, the INE has begun to work on incorporating the new National Classification of Economic Activities CNAE-2025 in all its statistical operations.
In the case of the Statistics on the use of biotechnology, the first publication of results with CNAE-2025 will take place in 2027.
The objective of the Statistics on the use of Biotechnology is to measure national efforts in biotechnology-related activities, in order to provide the necessary information for adequate decision-making in scientific-technological policy.
In this regard, the objective is to ascertain the type of biotechnology-related activities that are carried out in each of the sectors in which the economy is divided; the final application areas of the products obtained via the development of biotechnologies; and the economic and human resources appointed to the biotechnology-related productive and investigation activity in Spain.
For more information, you can access the methodology and the standardised methodological report.
INE statistics are produced in accordance with the Code of Good Practice for European Statistics. More information on Quality at INE and the Code of Best Practices.